GlassScriptPhysician profile
Trayton B Mains
NPI 1720217383
$3,657.50
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $482 · 2021: $828 · 2022: $958 · 2023: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.45 | 2019-2023 | |
| Amgen INC. | $510.40 | 2019-2023 | Tavneos, Enbrel |
| Novartis Pharmaceuticals Corporation | $331.82 | 2019-2023 | |
| Lilly USA, LLC | $249.55 | 2019-2023 | Taltz |
| Collegium Pharmaceutical, INC. | $246.41 | 2019-2022 | |
| Janssen Biotech, INC. | $229.23 | 2019-2023 | Tremfya |
| Pfizer INC. | $188.78 | 2019-2022 | |
| Ucb, INC. | $186.36 | 2019-2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $164.93 | 2019-2023 | Orencia |
| Alexion Pharmaceuticals, INC. | $118.60 | 2021-2023 | Strensiq, Ultomiris |
| Astrazeneca Pharmaceuticals LP | $104.00 | 2022-2023 | Saphnelo |
| Aurinia Pharma U.S., INC. | $67.78 | 2021-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $66.94 | 2022-2023 | Acthar |
| Radius Health, INC. | $58.31 | 2020-2023 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $50.83 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $49.22 | 2022-2023 | Renflexis, Hadlima |
| Genentech USA, INC. | $49.13 | 2022-2023 | Rituxan, Actemra |
| Glaxosmithkline, LLC. | $47.11 | 2019-2022 | |
| Stryker Corporation | $37.64 | 2022 | |
| Horizon Therapeutics Plc | $30.94 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $21.12 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.50 | 2022 | |
| Sobi, INC | $18.88 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.25 | 2022 | |
| Zyla Life Sciences, INC. | $16.84 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.38 | 2021 | |
| Merz North America, INC. | $14.87 | 2019 | |
| Lundbeck LLC | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trayton Mains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.